| Primary |
| Acute Coronary Syndrome |
27.0% |
| Acute Myocardial Infarction |
20.4% |
| Coronary Artery Disease |
8.3% |
| Hypertension |
7.9% |
| Myocardial Infarction |
7.2% |
| Stent Placement |
5.1% |
| Thrombosis Prophylaxis |
4.4% |
| Hypercholesterolaemia |
2.7% |
| Atrial Fibrillation |
2.1% |
| Percutaneous Coronary Intervention |
2.0% |
| Diabetes Mellitus |
1.7% |
| Myocardial Ischaemia |
1.6% |
| Angina Unstable |
1.4% |
| Infarction |
1.4% |
| Antiplatelet Therapy |
1.3% |
| Cardiac Disorder |
1.3% |
| Angina Pectoris |
1.0% |
| Anticoagulant Therapy |
1.0% |
| Gastritis Prophylaxis |
1.0% |
| Ischaemic Heart Disease Prophylaxis |
1.0% |
|
| Thrombosis In Device |
20.6% |
| Thrombocytopenia |
10.1% |
| Dyspnoea |
7.9% |
| Death |
6.9% |
| Cerebral Haemorrhage |
5.8% |
| Haemorrhage |
5.3% |
| Drug Ineffective |
3.7% |
| Melaena |
3.7% |
| Subdural Haematoma |
3.7% |
| Atrioventricular Block Complete |
3.2% |
| Bradycardia |
3.2% |
| Myocardial Infarction |
3.2% |
| Post Procedural Haemorrhage |
3.2% |
| Rhabdomyolysis |
3.2% |
| Thrombosis |
3.2% |
| Atrioventricular Block |
2.6% |
| Malaise |
2.6% |
| Pain In Extremity |
2.6% |
| Renal Failure |
2.6% |
| Sinus Arrest |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
20.6% |
| Acute Myocardial Infarction |
20.4% |
| Acute Coronary Syndrome |
12.6% |
| Coronary Artery Disease |
10.3% |
| Myocardial Infarction |
9.0% |
| Stent Placement |
5.1% |
| Hypertension |
3.1% |
| Thrombosis Prophylaxis |
2.9% |
| Coronary Artery Bypass |
2.2% |
| Coronary Arterial Stent Insertion |
2.1% |
| Blood Cholesterol Increased |
1.5% |
| Cardiac Disorder |
1.5% |
| Pneumonia |
1.5% |
| Dementia Alzheimer's Type |
1.3% |
| Atrial Fibrillation |
1.2% |
| Angina Unstable |
1.0% |
| Intracardiac Thrombus |
1.0% |
| Percutaneous Coronary Intervention |
1.0% |
| Diabetes Mellitus |
0.9% |
| Cardiac Failure |
0.7% |
|
| Thrombosis In Device |
14.3% |
| Transaminases Increased |
11.6% |
| Panic Attack |
8.9% |
| Subdural Haematoma |
7.1% |
| Thrombocytopenia |
6.3% |
| Unresponsive To Stimuli |
6.3% |
| Dyspnoea |
5.4% |
| Haemorrhage |
5.4% |
| Rhabdomyolysis |
4.5% |
| Haematoma |
3.6% |
| Haemorrhagic Stroke |
3.6% |
| Bradycardia |
2.7% |
| Cerebral Haemorrhage |
2.7% |
| Hepatic Necrosis |
2.7% |
| Impaired Driving Ability |
2.7% |
| Ischaemic Stroke |
2.7% |
| Pain In Extremity |
2.7% |
| Type 2 Diabetes Mellitus |
2.7% |
| Vomiting |
2.7% |
| Angioedema |
1.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
19.1% |
| Hypertension |
9.6% |
| Prophylaxis |
7.8% |
| Cardiovascular Event Prophylaxis |
6.1% |
| Diabetes Mellitus |
5.2% |
| Myocardial Infarction |
5.2% |
| Rheumatoid Arthritis |
5.2% |
| Acute Myocardial Infarction |
4.3% |
| Osteoporosis |
4.3% |
| Type 2 Diabetes Mellitus |
4.3% |
| Abdominal Pain Upper |
3.5% |
| Acute Coronary Syndrome |
3.5% |
| Infarction |
3.5% |
| Pain |
3.5% |
| Angioplasty |
2.6% |
| Cardiac Disorder |
2.6% |
| Coronary Artery Disease |
2.6% |
| Coronary Revascularisation |
2.6% |
| Endocarditis |
2.6% |
| Cardiac Failure |
1.7% |
|
| Myocardial Infarction |
10.7% |
| Rhabdomyolysis |
10.7% |
| Dyspnoea |
7.1% |
| Long Qt Syndrome |
7.1% |
| Thrombocytopenia |
7.1% |
| Ventricular Fibrillation |
7.1% |
| Acute Coronary Syndrome |
3.6% |
| Bradycardia |
3.6% |
| Cardiac Arrest |
3.6% |
| Cardiac Operation |
3.6% |
| Drug Ineffective |
3.6% |
| Drug Interaction |
3.6% |
| Dyspnoea At Rest |
3.6% |
| Encephalopathy |
3.6% |
| Gamma-glutamyltransferase |
3.6% |
| Gamma-glutamyltransferase Increased |
3.6% |
| Heart Rate Irregular |
3.6% |
| Hypoglycaemia |
3.6% |
| Hypokalaemia |
3.6% |
| Incorrect Route Of Drug Administration |
3.6% |
|
| Interacting |
| Product Used For Unknown Indication |
28.1% |
| Coronary Artery Disease |
12.3% |
| Thrombosis Prophylaxis |
10.5% |
| Acute Coronary Syndrome |
7.0% |
| Hypertension |
7.0% |
| Oedema |
5.3% |
| Anticoagulant Therapy |
3.5% |
| Chest Pain |
3.5% |
| Hypercholesterolaemia |
3.5% |
| Pain |
3.5% |
| Stent Placement |
3.5% |
| Type 2 Diabetes Mellitus |
3.5% |
| Depression |
1.8% |
| Hypertension Arterial |
1.8% |
| Percutaneous Coronary Intervention |
1.8% |
| Prophylaxis |
1.8% |
| Stemi |
1.8% |
|
| Drug Interaction |
20.0% |
| Rhabdomyolysis |
20.0% |
| Lung Neoplasm Malignant |
10.0% |
| Melaena |
10.0% |
| Myalgia |
10.0% |
| Oedema |
10.0% |
| Puncture Site Haemorrhage |
10.0% |
| Urine Abnormality |
10.0% |
|
